Elixir Pharmaceuticals, Inc.

Laboratoires Serono S.a.

Jean-Francois Pons

Jeffrey O Saunders

Manuel A Navia

Rory A Curtis

Peter DiStefano

Andrew Napper

Jay R Luly

Russell Thomas

Agnes Bombrun

Dominique Swinnen

Thomas Stephen Coulter

Thomas E McDonagh

Jonathan M Solomon

L Julie Huber

Russel J Thomas

Jeffrey Hixon

Paul Mortenson

Russell J Thomas

Thomas Mcdonagh

Rory Curtis

RussellJ Thomas

Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.

SirT inhibitors that bind to NAD

Compounds of formula (I) are described herein  The compounds can be used, for example, to modulate growth hormone secretagogue receptor (GHS-R). In some instances, the compounds can be used to treat obesity.

Therapeutic compounds and uses thereof

Compounds that modulate GHS-R are described, for examples compounds formula (I) 

Sulfonamide compounds and uses thereof

Compounds of formula (I) are described herein The compounds can be used, for example, to modulate growth hormone secretagogue receptor (GHS-R). In some instances, the compounds can be used to treat obesity.

The present invention is related to aryl dicarboxamides of formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholes-terolemia, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of aryl dicarboxamides of formula (I) to modulate, notably to inhibit the activity of PTPs. A is an aminocarbonyl moiety; Cy is an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group; n is either 0 or 1; Rand Rare independently from each other is selected from the group consisting of hydrogen or C-C-alkyl; Rand Rare each independently from each other selected from the group consisting of H, hydroxy, C-Calkyl, carboxy, C-Calkoxy, C-Calkyl carboxy, C-Calkenyl carboxy, C-Calkynyl carboxy, amino or Rand Rmay form an unsaturated or saturated heterocyclic ring, whereby at least one of Ror Ris not a hydrogen or C-Calkyl 

Aryl dicarboxamides

Growing community of inventors

Abingdon, United Kingdom

Jean-Francois Pons